MRNA news, real time MRNA stock news, Moderna news today

News

MRNA

42.00

+0.11%

0.05

Moderna shares drop after FDA refuses to file for mRNA-1010 influenza vaccine

Seeking Alpha · 2h ago

FDA Issues Refusal-to-File Letter For Moderna's Investigational Flu Vaccine MRNA-1010; Stock Down

NASDAQ · 4h ago

PRESS DIGEST -Wall Street Journal - February 11

Reuters · 4h ago

‘Complete Stunner!’ Moderna Stock Plunges as FDA Refuses Flu Vaccine Review

TipRanks · 4h ago

FDA Refuses to Review Moderna's Application for New Flu Vaccine -- 2nd Update

The Wall Street Journal · 10h ago

Stocks to Watch: Moderna, Lyft, Cloudflare, Angi

Dow Jones · 11h ago

BUZZ-Moderna shares slump after FDA refuses to review new flu vaccine

Reuters · 11h ago

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

Dow Jones · 11h ago

UPDATE 2-Moderna says US FDA refuses to review its influenza vaccine

Reuters · 11h ago

Moderna Obtains Refusal-To-File Letter From FDA For Its Investigational Seasonal Influenza Vaccine, mRNA-1010; Does Not Expect Any Impact On Its 2026 Financial Guidance; Letter Did Not Identify Any Specific Safety Or Efficacy Concerns Regarding mRNA-1010; Refusal To Review Submission Is Inconsistent With Feedback At Pre-Phase 3 And Pre-Submission Consultations; Has Requested A Type A Meeting With CBER To Understand Basis For RTF Letter

Benzinga · 11h ago

Moderna receives RTF letter from FDA for mRNA-1010

TipRanks · 11h ago

*Moderna: Does Not Expect Any Impact on Its 2026 Fincl Guidance >MRNA

Dow Jones · 11h ago

*Moderna: Refusal to Review the Submission Is Inconsistent With Feedback at Pre-Phase 3 and Pre-Submission Consultations >MRNA

Dow Jones · 11h ago

*Moderna: Requested a Type A Meeting to Understand the Path Forward >MRNA

Dow Jones · 11h ago

FDA REFUSES TO CONSIDER APPROVING USE OF MODERNA’S NEW FLU VACCINE - WSJ

Reuters · 11h ago

RPT - MODERNA: RECEIVES REFUSAL-TO-FILE LETTER FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ITS INVESTIGATIONAL SEASONAL INFLUENZA VACCINE, MRNA-1010

Reuters · 11h ago

FDA Refuses to Review Moderna Flu Vaccine Over Comparator Choice

Reuters · 11h ago

FDA Refuses to Review Moderna's Application for New Flu Vaccine

The Wall Street Journal · 11h ago

Assessing Moderna (MRNA) Valuation As Earnings And Pipeline Updates Draw Investor Focus

Simply Wall St · 15h ago

1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell

NASDAQ · 16h ago

Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.

About MRNA

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).